Joseph Roland
Managing Director
Last active: 10/5/2017

MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma:  A Comparison With AMACR.

Goldstein J, Goyal R, Roland JT, Gellert LL, Clark PE, Hameed O, Giannico GA
Am J Clin Pathol. 2016 146 (3): 294-302

PMID: 27543977 · DOI:10.1093/ajcp/aqw111

OBJECTIVES - We compared the utility of membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2) and α-methylacyl CoA (AMACR) by immunohistochemistry in diagnosing prostatic adenocarcinoma.

METHODS - Seventy-eight radical prostatectomies were used to construct three tissue microarrays with 512 cores, including benign prostatic tissue, benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia (HGPIN), and adenocarcinoma. AMACR and MAGI-2 immunohistochemistry were evaluated by visual and image analysis.

RESULTS - MAGI-2 and AMACR were significantly higher in adenocarcinoma and HGPIN compared with benign tissue. At H-score cutoffs of 300 and 200, MAGI-2 was more accurate in distinguishing benign from malignant glands than AMACR. Areas under the curve by image and visual analysis were 0.846 and 0.818 for MAGI-2 and 0.937 and 0.924 for AMACR, respectively. The accuracy of MAGI-2 in distinguishing benign from malignant glands on the same core was higher (95% vs 88%).

CONCLUSIONS - MAGI-2 could represent a useful adjunct for diagnosis of prostatic adenocarcinoma, especially when AMACR is not discriminatory.

© American Society for Clinical Pathology, 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

MeSH Terms (14)

Adenocarcinoma Biomarkers, Tumor Carrier Proteins Diagnosis, Differential Humans Male Prostate Prostatectomy Prostatic Hyperplasia Prostatic Intraepithelial Neoplasia Prostatic Neoplasms Racemases and Epimerases Sensitivity and Specificity Tissue Array Analysis

Connections (1)

This publication is referenced by other Labnodes entities:

Links